01
Qualification before quotation
Legal identity, manufacturing status, product evidence and supply authority are screened before an opportunity advances.
Quality, compliance & governance
Evidence is the operating currency of regulated healthcare.
ORBIWAY applies risk-based qualification, document control and transparent responsibility mapping to help stakeholders make defensible decisions.
Request a document discussionQuality framework
Four control pillars from qualification through delivery.
The depth of review is calibrated to product type, source, destination, urgency and transaction structure.
02
Document-led execution
Each mandate is mapped to an engagement-specific document matrix covering quality, regulatory, commercial and logistics evidence.
03
Traceable decision-making
Versions, assumptions, responsibilities and exceptions are recorded so stakeholders can act with a clear audit trail.
04
Risk-based escalation
Cold chain, controlled medicines, biologics, short shelf life and urgent tenders receive enhanced review and governance.
Illustrative document matrix
The evidence stack is built around the transaction—not copied from a generic checklist.
Actual requirements vary by country, authority, product class and procurement method.
Control areaTypical evidenceDecision purpose
Corporate & authorityLegal registration, licences, manufacturer authorisation, supply authorityConfirm who may manufacture, offer and supply
Manufacturing qualityGMP/inspection evidence, manufacturing licence, quality agreements, audit statusAssess site and quality-system standing
Product & market statusCPP, marketing authorisation, dossier status, artwork, specifications, IFUTest destination-market feasibility
Batch & releaseCOA, batch details, expiry, shelf life, release evidence, serialization dataConfirm product-level supply position
Commercial & logisticsOffer basis, Incoterm, lead time, capacity, route, cold chain, insuranceValidate the executable landed proposition
Enhanced diligence triggers
Higher-risk categories require deeper review and clearer escalation.
Cold chain, biologics, oncology, controlled medicines, blood derivatives, very short shelf life, emergency sourcing and non-registered supply pathways may require specialist legal, regulatory and quality input.
Chain-of-custody and temperature evidence
Anti-counterfeit and source-authority review
Import-permit and controlled-product pathway
Pharmacovigilance and post-market responsibilities
Deviation, recall and complaint escalation
Sanctions, ethics and third-party due diligence
Frequently asked
Clear answers before documentation begins.
Does ORBIWAY hold every certification referenced on this website?+
No. Named standards describe frameworks that may apply to a manufacturer, product, logistics provider or engagement. Certification and regulatory status are verified for the exact legal entity, site and product before reliance.
Can ORBIWAY support non-registered or shortage products?+
Potentially, where the destination market provides a lawful pathway and the relevant authority, buyer and qualified professionals approve it. Feasibility is assessed case by case.
How are confidential dossiers and tender files handled?+
Initial inquiries should contain only the minimum necessary details. Sensitive files are exchanged after counterparties, purpose, authority and confidentiality controls are confirmed.
Does an inquiry create a supply or representation commitment?+
No. Commitments arise only through authorised written agreements after regulatory, quality, commercial and operational review.
Website governance
Privacy, terms and cookies
Privacy notice
Business contact information submitted through this website is used to assess and respond to inquiries, manage counterparties and maintain appropriate commercial records. Do not submit patient data, special-category personal data or confidential dossiers through the initial form. You may request access, correction or deletion subject to applicable legal and record-retention obligations.
Terms of use
Website content is general corporate information and does not constitute a product offer, medical advice, regulatory opinion, guarantee of availability or binding commercial commitment. Any transaction remains subject to contract, eligibility, regulatory approval and due diligence.
Cookie position
This release is designed without advertising cookies. Essential technical storage may be used for security and reliable operation. Analytics or third-party tracking should be activated only after an appropriate consent mechanism and policy update are implemented.
Start a focused conversation
Align the documentation pathway before commercial deadlines take control.
Share the destination, product class and procurement route. ORBIWAY can help define the first evidence matrix and decision sequence.